Cargando…

ACE2, COVID19 and serum ACE as a possible biomarker to predict severity of disease

Detalles Bibliográficos
Autor principal:	Skarstein Kolberg, Espen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129721/ https://www.ncbi.nlm.nih.gov/pubmed/32283335 http://dx.doi.org/10.1016/j.jcv.2020.104350

Ejemplares similares

Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease
por: Sabater Molina, Maria, et al.
Publicado: (2022)

Association investigations between ACE1 and ACE2 polymorphisms and severity of COVID-19 disease
por: Najafi, Mojtaba, et al.
Publicado: (2022)

ACE and ACE2 Gene Variants Are Associated With Severe Outcomes of COVID-19 in Men
por: Martínez-Gómez, Laura E., et al.
Publicado: (2022)

Genotype variation of ACE and ACE2 genes affects the severity of COVID-19 patients
por: Faustine, Ingrid, et al.
Publicado: (2023)

Effects of PM2.5 Exposure on the ACE/ACE2 Pathway: Possible Implication in COVID-19 Pandemic
por: Botto, Laura, et al.
Publicado: (2023)

ACE2 and Diabetes: ACE of ACEs?
por: Batlle, Daniel, et al.
Publicado: (2010)

ACE2 Elevation in Severe COVID-19
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2021)

ACE2 and COVID-19 Susceptibility and Severity
por: Zheng, Ming
Publicado: (2022)

The ACE rs1799752 Variant Is Associated with COVID-19 Severity but Is Independent of Serum ACE Activity in Hospitalized and Recovered Patients
por: Fricke-Galindo, Ingrid, et al.
Publicado: (2023)

Assessment of ACE1 variants and ACE1/ACE2 expression in COVID-19 patients
por: Akbari, Mohammadarian, et al.
Publicado: (2022)

The Role of ACE, ACE2, and AGTR2 Polymorphisms in COVID-19 Severity and the Presence of COVID-19-Related Retinopathy
por: Jevnikar, Kristina, et al.
Publicado: (2022)

Dysbalance of ACE2 levels – a possible cause for severe COVID‐19 outcome in COPD
por: Fließer, Elisabeth, et al.
Publicado: (2021)

ACE and ACE2: insights from Drosophila and implications for COVID-19
por: Herrera, Paul, et al.
Publicado: (2021)

Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
por: Abd El-Aziz, Tarek Mohamed, et al.
Publicado: (2020)

ACE/ACE2 Ratio: A Key Also in 2019 Coronavirus Disease (Covid-19)?
por: Pagliaro, Pasquale, et al.
Publicado: (2020)

ACE/ACE2 balance might be instrumental to explain the certain comorbidities leading to severe COVID-19 cases
por: Bank, Sarbashri, et al.
Publicado: (2021)

Circulating ACE2 activity predicts mortality and disease severity in hospitalized COVID-19 patients
por: Fagyas, Miklós, et al.
Publicado: (2022)

Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19
por: Townsend, Alain
Publicado: (2020)

Human recombinant soluble ACE2 in severe COVID-19
por: Zoufaly, Alexander, et al.
Publicado: (2020)

ACE2, Metformin, and COVID-19
por: Malhotra, Atul, et al.
Publicado: (2020)

ACE2 Serum Levels as Predictor of Infectability and Outcome in COVID-19
por: Maza, María del Carmen, et al.
Publicado: (2022)

The Impact of ACE2 Polymorphisms on COVID-19 Disease: Susceptibility, Severity, and Therapy
por: Chen, Fei, et al.
Publicado: (2021)

Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome
por: Gómez, Juan, et al.
Publicado: (2020)

Role of ACE, ACE2 and Neprilysin in the Kidney
por: Chappell, Mark C.
Publicado: (2007)

S19. THE ROLE OF ACE AS POSSIBLE BIOMARKER FOR TREATMENT RESISTANCE TO ANTIPSYCHOTICS IN FIRST EPISODE OF PSYCHOSIS
por: Luisa, Longo, et al.
Publicado: (2020)

COVID-19: Acing the Treatment
por: Hunter, Jez, et al.
Publicado: (2022)

COVID-19 as a viral functional ACE2 deficiency disorder with ACE2 related multi-organ disease
por: Gan, Rosemary, et al.
Publicado: (2020)

GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility
por: Torrens-Mas, Margalida, et al.
Publicado: (2022)

ACE2 polymorphisms impact COVID-19 severity in obese patients
por: Jalaleddine, Nour, et al.
Publicado: (2022)

Blood ACE2 Protein Level Correlates with COVID-19 Severity
por: Shevchuk, Oksana, et al.
Publicado: (2023)

Scientific Hypothesis for Treatment of COVID‐19′s Lung Lesions by Adjusting ACE/ACE2 Imbalance
por: Ferrara, F., et al.
Publicado: (2021)

ACE/ACE2 Ratio and MMP-9 Activity as Potential Biomarkers in Tuberculous Pleural Effusions
por: Hsieh, Wen-Yeh, et al.
Publicado: (2012)

Off‐target ACE2 ligands: Possible therapeutic option for CoVid‐19?
por: Brogi, Simone, et al.
Publicado: (2020)

The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19
por: Bosso, Mira, et al.
Publicado: (2020)

Antihypertensive medication uses and serum ACE2 levels: ACEIs/ARBs treatment does not raise serum levels of ACE2
por: Emilsson, Valur, et al.
Publicado: (2020)

Manipulation of ACE2 expression in COVID-19
por: Chaudhry, Farhan, et al.
Publicado: (2020)

ACE2 and COVID-19 and the resulting ARDS
por: Zhang, Xiaoqing, et al.
Publicado: (2020)

ACE2 Shedding and the Role in COVID-19
por: Wang, Jieqiong, et al.
Publicado: (2022)

Angiotensin Converting Enzyme (ACE) and ACE2 Bind Integrins and ACE2 Regulates Integrin Signalling
por: Clarke, Nicola E., et al.
Publicado: (2012)

Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 as a biomarker for the severity of COVID-19
por: Fagyas, Miklós, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jlpqjfqglucami8mhc7lh1qeob